Improved metabolic profiles in insulin-treated diabetic patients given an alpha-glucosidehydrolase inhibitor.

Article Details

Citation

Walton RJ, Sherif IT, Noy GA, Alberti KG

Improved metabolic profiles in insulin-treated diabetic patients given an alpha-glucosidehydrolase inhibitor.

Br Med J. 1979 Jan 27;1(6158):220-1.

PubMed ID
369651 [ View in PubMed
]
Abstract

An alpha-glucosidehydrolase inhibitor (acarbose; BAY g 5421) taken with food was compared with dummy tablets in seven insulin-treated diabetic patients over eight-hour periods that included breakfast, lunch, and two snacks. Acarbose diminished the postprandial increases in blood glucose, lactate, and pyruvate concentrations and may therefore be of value in the management of insulin-dependent diabetes.

DrugBank Data that Cites this Article

Pharmaco-metabolomics
DrugDrug GroupsMetaboliteChangeDescription
AcarboseApproved InvestigationalLactate
decreased
Acarbose decreases the level of Lactate in the blood
AcarboseApproved InvestigationalPyruvate
decreased
Acarbose decreases the level of Pyruvate in the blood